Buscar resultados de ensayos clínicos
Peripheral T-cell Lymphoma - 26 Studies Found
Estado | Estudiar |
Completed |
Nombre del estudio: Study of Pralatrexate With Vitamin B12 and Folic Acid in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Condición: Peripheral T-cell Lymphoma Fecha: 2006-08-14 Intervenciones: Drug: Pralatrexate Injection Pralatrexate 30 mg/m2 via IV push over 3-5 minutes for 6 weeks in a 7 week |
Recruiting |
Nombre del estudio: Chidamide for Refractory/Relapsed Peripheral T Cell Lymphoma Condición: Peripheral T Cell Lymphoma Fecha: 2016-10-21 Intervenciones: Drug: Chidamide Chidamide is given to the patients as described, and drug concentration is measured in p |
Completed |
Nombre del estudio: E7777 for the Treatment of Patients With Peripheral T-Cell Lymphoma Condición: Peripheral T-Cell Lymphoma Fecha: 2011-07-18 Intervenciones: Biological: denileukin diftitox (E7777) E7777 will be administered by intravenous (IV) infusion for 5 da |
Active, not recruiting |
Nombre del estudio: Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment Registry Condición: Peripheral T-cell Lymphoma Fecha: 2010-04-23 |
Not yet recruiting |
Nombre del estudio: Chidamide With ICE Regimen for Relapsed/Refractory Peripheral T Cell Lymphoma Condición: Peripheral T Cell Lymphoma Fecha: 2016-07-24 Intervenciones: Drug: Chidamide with ICE regimen Chidamide and ICE regimen, dosage described in arm description |
Recruiting |
Nombre del estudio: Chidamide Plus Chemotherapy in the Treatment of Peripheral T-cell Lymphoma Condición: Peripheral T Cell Lymphoma Fecha: 2016-04-19 Intervenciones: Drug: Chidamide |
Completed |
Nombre del estudio: Alemtuzumab and CHOP Chemotherapy for Aggressive Histological Peripheral T-Cell Lymphomas Condición: Peripheral T-cell Lymphomas Fecha: 2007-03-27 Intervenciones: Drug: Alemtuzumab (Campath-1H) The investigational drug is alemtuzumab (Campath-1H). It is a recombinant |
Completed |
Nombre del estudio: A Phase 1 Study of SP-02L in Relapsed or Refractory Patients With Peripheral T-cell Lymphoma (PTCL) Condición: Peripheral T-cell Lymphoma Fecha: 2011-09-13 Intervenciones:
|
Active, not recruiting |
Nombre del estudio: Phase I/II Clinical Study of Pralatrexate in Japanese Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Condición: Peripheral T-cell Lymphoma Fecha: 2013-12-04 Intervenciones:
|
Recruiting |
Nombre del estudio: A Phase 2 Study of SP-02L in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) Condición: Peripheral T-Cell Lymphoma Fecha: 2015-12-25 Intervenciones: Drug: SP-02L (darinaparsin for injection) Darinaparsin 300 mg/m2 once daily for 5 consecutive days every |